Orit Gefen

Orit Gefen

Auto-generated profile, based on publicly available information

Orit Gefen

Racah Institute of Physics and the Harvey M. Kruger Family Center for Nanoscience and Nanotechnology, Edmond J. Safra Campus, The Hebrew University of Jerusalem, Jerusalem 91904, Israel

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2016 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
ABAsher Brauner
Asher Brauner
OFOfer Fridman
Ofer Fridman
OGOrit Gefen
Orit Gefen
NBNathalie Q. Balaban
Nathalie Q. Balaban

24 February 2017 in Science
Verified
Journal Article
Closed access
PDF file
ILIrit Levin-Reisman
Irit Levin-Reisman
IRIrine Ronin
Irine Ronin
OGOrit Gefen
Orit Gefen
IBIlan Braniss
Ilan Braniss
NSNoam Shoresh
Noam Shoresh
NBNathalie Q. Balaban
Nathalie Q. Balaban
Resistance on a background of tolerance: Bacteria survive antibiotic exposure either because they are quiescent when antibiotics are around in the highest concentrations (i.e., tolerance) or because they acquire active biochemical resistance mechanisms (i.e., resistance). Both tolerance and resistance involve the acquisition of mutations from the wild type. Levin-Reisman et al. used in vitro evolution experiments to show that populations of bacteria that become genetically resistant to the antibiotic ampicillin most quickly do so on a background of tolerance mutations (see the Perspective by Lewis and Shan). Because the probability of a tolerant organism surviving is higher, it has a greater chance of subsequently acquiring resistance mutations. Tolerance is often overlooked in the clinic but should in future be screened for and targeted more precisely to reduce the rates of acquired resistance. Science , this issue p. 826 ; see also p. 796

10 January 2020 in Science
Verified
Journal Article
Closed access
PDF file
JLJiafeng Liu
Jiafeng Liu
OGOrit Gefen
Orit Gefen
IRIrine Ronin
Irine Ronin
MBMaskit Bar-Meir
Maskit Bar-Meir
NBNathalie Q. Balaban
Nathalie Q. Balaban
Challenges of drug combinations: Combinations of antibiotics are used to treat intractable infections such as methicillin-resistant Staphylococcus aureus . Clinically, however, drugs tend to be used empirically, and results can be contradictory. Liu et al. translated observations made in vitro to patient samples to understand the role of antibiotic tolerance in promoting or suppressing resistance when drug combinations are used (see the Perspective by Berti and Hirsch). Although bacterial populations exposed to multiple antibiotics can develop tolerance to multiple drugs, one drug in a combination may be able counter resistance to a partner drug and provide effective therapy. However, if tolerance has already emerged to one drug, the combination may end up promoting the transmission of resistance to a partner drug. Science , this issue p. 200 ; see also p. 141

1 July 2009 in FEMS Microbiology Reviews
Verified
Journal Article
Closed access
OGOrit Gefen
Orit Gefen
NBNathalie Q. Balaban
Nathalie Q. Balaban

1 August 2010 in Nature Methods
Verified
Journal Article
Closed access
ILIrit Levin-Reisman
Irit Levin-Reisman
OGOrit Gefen
Orit Gefen
OFOfer Fridman
Ofer Fridman
IRIrine Ronin
Irine Ronin
DSDavid Shwa
David Shwa
NBNathalie Q Balaban
Nathalie Q Balaban

16 December 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
OGOrit Gefen
Orit Gefen
OFOfer Fridman
Ofer Fridman
IRIrine Ronin
Irine Ronin
NBNathalie Q. Balaban
Nathalie Q. Balaban
Exponentially growing bacteria are rarely found in the wild, as microorganisms tend to spend most of their lifetime at stationary phase. Despite this general prevalence of stationary-phase bacteria, they are as yet poorly characterized. Our goal was to quantitatively study this phase by direct observation of single bacteria as they enter into stationary phase and by monitoring their activity over several days during growth arrest. For this purpose, we devised an experimental procedure for starving single Escherichia coli bacteria in microfluidic devices and measured their activity by monitoring the production rate of fluorescent proteins. When amino acids were the sole carbon source, the production rate decreased by an order of magnitude upon entry into stationary phase. We found that, even while growth-arrested, bacteria continued to produce proteins at a surprisingly constant rate over several days. Our identification of this newly observed period of constant activity in nongrowing cells, designated as constant activity stationary phase, makes possible the conduction of assays that require constant protein expression over time, and are therefore difficult to perform under exponential growth conditions. Moreover, we show that exogenous protein expression bears no fitness cost on the regrowth of the population when starvation ends. Further characterization of constant activity stationary phase—a phase where nongrowing bacteria can be quantitatively studied over several days in a reproducible manner—should contribute to a better understanding of this ubiquitous but overlooked physiological state of bacteria in nature. Significance Although most laboratory work is performed on dividing bacteria, in the wild bacteria spend most of their lifetime in the stationary phase, scarcely dividing. To study the stationary phase, we developed a method of tracking nondividing bacteria at the single cell level and characterizing their response to external stimulation. While following bacteria under growth-arrest conditions, we found that they maintain surprisingly constant activity for several days after entering the stationary phase. These bacteria were able to produce proteins without significant cost to their viability or regrowth dynamics. Moreover, this constant-activity stationary phase enables the measurement of different bacterial characteristics, which are difficult to perform under exponential growth conditions.